Study Objectives: We investigated the prevalence and hazard ratios for insomnia complaints in a large cohort of middle-aged men and women. Design: The Atherosclerosis Risk in Communities Study is a prospective study of cardiovascular disease. Using multivariate regression analysis, we predicted the likelihood of endorsing the insomnia complaints by age, sex, alcohol intake, smoking, diabetes, heart disease, menopausal status, use of hypnotics, hypertension, depressive symptoms, education level, body mass index, respiratory symptoms, and pulmonary function status. We predicted the hazard ratios (HR) of death at 6.3 ± 1.1 year by endorsement of insomnia complaints and by hypnotic use controlling for covariates. Setting: North American communities. Participants: 13563 participants aged 45 to 69 years at baseline Interventions: None.
INTRODUCTION

INSOMNIA IS ESTIMATED TO AFFECT AS MANY AS ONE THIRD OF AMERICANS. WHILE THE PREVALENCE OF IN-SOMNIA DEPENDS ON HOW IT IS DEFINED AND diagnosed,
it is easily the most commonly reported sleep problem.
1,2 Insomnia is more prevalent in women than in men at all ages. [1] [2] [3] [4] [5] [6] Other reported risks for insomnia include aging, 4 ,5 medical illness, 4, 5, 7, 8 sleep apnea, 9 depression and other psychiatric illness, 3, 6 and some lifestyle factors. 10 Insomnia is associated with reduced quality of life and may precede depression 3, 7 but has not been shown to be causally associated with adverse outcomes. In fact, Kripke et al 11 found a reduced mortality rate for those individuals complaining of sleeping difficulty on 6-year follow-up. On the other hand, both long sleep and short sleep are associated with increased morbidity and mortality in population-based studies, [11] [12] [13] as is the use of hypnotics. 11, 14 The purpose of this study was to use well-established cohort data to investigate correlates and outcomes of insomnia complaints and hypnotic use.
METHODS
Participants
The Atherosclerosis Risk in Communities (ARIC) study is a prospective study of the natural history and etiology of atherosclerotic disease and the rates of cardiovascular disease events and is described in detail elsewhere. 15 The study cohort was as a probability sample of men and women aged 44 to 66 years from 4 communities in the United States: Forsyth County, North Carolina (Winston-Salem); Jackson, Mississippi; Washington County, Maryland. (Hagerstown); and suburbs of Minneapolis, Minnesota. Baseline examinations, tests, and interviews were conducted between 1987 and 1989, and participants subsequently were contacted on an annual basis. Survivors were invited to take part in 3 follow-up data collections at intervals of approximately 3 years. In this analysis, we used data from the second visit as the baseline for establishment of behavioral and sociodemographic variables and used survival at follow-up (mean, 6.3 ± 1.1 years) as a dependent variable. The study objectives, design, sampling scheme, and cohort examination procedures have been described. 15 
Variable Measurement and Definitions
Most measurements reported here were collected at the second ARIC examination (1990) (1991) (1992) . Three sleep complaints were available as part of the Maastricht questionnaire: "Do you often have trouble falling asleep?" (difficulty falling asleep); "Do you wake up repeatedly during the night?" (sleep continuity disturbance); and "Do you ever wake up with a feeling of exhaustion and fatigue?" (nonrestorative sleep). 16 Age was stratified into 5 categories: 45 to 49, 50 to 54, 55 to 59, 60 to 64, and 65 to 69 years. Menopausal status was classified, based on self report, into 5 categories: premenopausal, perimenopausal, postmenopausal (natural), postmenopausal (surgical), and unknown. Race was classified, based on self-report, as black or white. Education level was categorized as less than high school, completion of high school, or more than high school. Body mass index was calculated as weight divided by height squared (kg/m 2 ) and divided into 4 categories; < 20, 20 to 24, 25 to 29, and ≥ 30. We screened for depressive symptoms with the Maastricht Questionnaire, 16 which was developed to assess vital exhaustion. The Maastricht Questionnaire is a 21-item self-administered questionnaire, a subset of which correlates with depression, 17 and which has been used to identify those with depressive symptoms in previous reports of the ARIC population. 18 We considered depressive symptoms to be present for those who responded positively to 4 or more of the 13-item subset of questions, which have been used to identify depressive symptoms in other reports. 17, 18 Those who met this criterion constituted the upper quartile of responses by this cohort.
Cardiac disease was considered present if the subject either self-reported a myocardial infarction, had been hospitalized for a myocardial infarction, or had evidence on the electrocardiogram of a myocardial infarction. Using a modification of the criteria developed by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), subjects were classified according to their GOLD stages of chronic obstructive pulmonary disease: GOLD stage 3 or 4 (forced expiratory volume in 1 second/forced vital capacity [FEV 1 /FVC ] < 0.70 and FEV 1 < 50% predicted), GOLD stage 2 (FEV 1 /FVC < 0.70 and FEV 1 ≥ 50% to < 80% predicted), GOLD stage 1 (FEV 1 /FVC < 0.70 and FEV 1 ≥ 80% predicted), restricted (FEV 1 /FVC ≥ 0.70 and FVC < 80% predicted), GOLD stage 0 (presence of respiratory symptoms in the absence of any lung-function abnormality), and no lung disease. 19 Systolic and diastolic fifth-phase blood pressures were measured 3 times using a random 0 sphygmomanometer in the right arm in seated participants. The mean of the last 2 measurements was used in the analyses. Hypertension was defined as a systolic blood pressure of > 160 mm Hg or diastolic > 95 mm Hg or the use of antihypertensives. Respondents with positive responses to "Have you ever smoked cigarettes?" and "Do you now smoke cigarettes?" were classified as "ever smokers" and "current smokers," respectively. Current intake of beer, wine, and liquor was summarized as drinks per week. We classified subjects as never, former, light (< 1 drink/week), moderate (1-13 drinks/week), or heavy drinkers (≥ 14 drinks/week). Diabetes was defined as a fasting glucose of > 126 mg/dL or a self-reported history of or treatment for diabetes. Data about medication use were collected during a 3-stage interview conducted by trained ARIC study personnel. The interview was conducted and data were recorded using a standardized 4-page ARIC Medication Survey Form. 20 Date of death was obtained from the death certificate, and the time from the evaluation to death was calculated.
Analysis
All analyses were conducted with SAS version 8.2 (SAS Institute, Cary, NC), SUDAAN version 8.0 (RTI, Research Triangle Park, NC), and SPSS version 10 (SPSS Inc, Chicago, Ill). Our primary outcome of interest was death, and the main predictors of interest in our analysis were sleep complaints and hypnotic use. For purposes of this investigation, we defined insomnia complaints as being present if the respondent endorsed either difficulty falling asleep or staying asleep, as well as having a complaint of nonrestorative sleep. In a separate analysis, we also predicted the likelihood of death by use of hypnotics at baselines; hypnotics were classified as benzodiazepines, barbiturates, or antihistamines. Cox proportional hazard regression models were developed using the SUDAAN procedure SURVIVAL to account for differential follow-up in ARIC participants. Time of follow-up was used as the underlying time metric. For deaths, the exit date was the date of death reported on the death certificate, and, for survivors, the exit date was the date the participant was last known to be alive. Plots of the log-log survival curves for each covariate were used to show that the proportional hazards assumptions were met. In predicting death by sleep complaints, age, sex, race, smoking status, alcohol ingestion, depressive symptoms, body mass index, diabetes, hypertension, heart disease, menopausal status, pulmonary function (GOLD class), and use of hypnotics were included in the adjusted models, and the models were evaluated for interactions. In predicting death from hypnotic use, we adjusted for the same covariates (except hypnotic use) and performed analyses both with and without controlling for sleep complaints.
We also performed logistic regression analysis of the factors predicting insomnia complaints (difficulty falling asleep OR sleep continuity disturbance AND nonrestorative sleep). Models were adjusted for age, sex, menopausal status, education level, body mass index, depressive symptoms, presence of cardiac disease, lung function status, presence of hypertension, smoking status, alcohol intake, diabetes, and hypnotic use.
RESULTS
Data were available from 13,564 participants in the second ARIC visit (Table 1) ; 2914 (21.5%) endorsed difficulty falling asleep, and 5173 (38.5%) endorsed waking up repeatedly. Of those participants who endorsed difficulty falling asleep, a majority (74%) also had problems with waking up repeatedly. Twentythree per cent of respondents had insomnia complaints (difficulty falling asleep or waking up repeatedly and nonrestorative sleep). With a more restrictive definition requiring all 3 of the sleep complaints, the prevalence was 9.6%.
Risk factors for insomnia complaints were female sex (OR 0.56, CI 0.45-0.70 for men), annual family income less than $50,000 (OR 1.23, CI 1.09-1.40), depressive symptoms (OR 5.05, CI 4.60-5.55), heart disease (OR 1.89, CI 1.67-2.14), severe airflow obstruction (OR 1.61, CI 1.17-2.22), pulmonary symptoms with normal pulmonary function (OR 1.71, CI 1.5-1.95), and restrictive lung disease (OR 1.27, CI 1.10-1.47) Seven hundred nine (5.2%) of the cohort died during follow-up. Risk factors for death at follow-up were age, male sex, less than high school education, body mass index < 20, depressive symptoms, heart disease, severe obstructive or restrictive pulmonary disease or symptoms, current or former cigarette smoking, former or never alcohol use, or diabetes. After controlling for covariates, insomnia complaints were not associated with an increased risk of death at 6.3-year follow-up. In fact, after controlling only for depressive symptoms, insomnia complaints were not associated with an increased risk of death (Table 3) .
Less than 3% of this population was identified as users of hypnotics (Table1). Controlling for confounders, the use of any sleeping pill or the specific use of barbiturates, antihistamines, or benzodiazepines was not associated with an increased risk of death at 3 years (Table 3) .
DISCUSSION
In this cohort, the complaints of difficulty with sleep onset, difficulty with sleep maintenance, and nonrestorative sleep were 21.5%, 38.5%, and 43.7%, respectively. If we considered insomnia complaints to be present if the subjects had either a complaint of difficulty falling asleep or of difficulty staying asleep plus nonrestorative sleep, the prevalence was 23%; if the definition required all 3 of the sleep complaints, the prevalence was 9.6%. No single insomnia complaint was associated with excess mortality in this carefully characterized population of adults. We also found that the use of sleeping pills did not predict likelihood of death, although the numbers of participants using sleeping pills in this study was small.
The current study has several strengths. First is our ability to evaluate insomnia complaints that include a problem of both sleep onset or maintenance, as well as the daytime consequence of nonrestorative sleep. Although we do not have precise frequency or duration data, the word "often" is included in the question about difficulty falling asleep. Further, the ARIC population of more than 13,000 well-characterized individuals is the largest North American cohort for which the prevalence and consequences of sleep complaints has been reported.
The definition of insomnia complaints used in this study is not entirely consistent with standard International Classification of Sleep Disorders or Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnostic criteria for insomnia. The lack of information about frequency or duration of insomnia complaints, or about the degree of distress or functional impairments caused by these complaints, raises some important limitations about the conclusions and precludes any distinction between insomnia syndrome and symptoms. This liberal definition may very well have contributed to the inflation of the prevalence estimates. In addition, there is no time reference to determine whether such estimates represent point, past year, or lifetime prevalence. However, Ohayon and others point out that lack of a standardized definition of insomnia and variability in the populations in which it has been studied have contributed to our confusion about the causes and sequelae of insomnia. 2, 6 In some prevalence estimates of "insomnia," the definition of insomnia is left entirely to the respondent. 11 There are several characterizations of insomnia in the literature: difficulty falling asleep; difficulty staying asleep, early morning awakening, and nonrestorative sleep. 25 In sum, the criteria and definitions for insomnia remain in flux and are not standardized. It is thus not surprising that both prevalence estimates and putative consequences of insomnia vary widely. Inclusion of a requirement for daytime consequences (sleepiness, irritability, nonrestorative sleep) has been done in a few studies, 3, [26] [27] [28] and the range of prevalence estimates of insomnia with daytime consequences is 9% to 16%. Our finding of 23% in individuals reporting either difficulty going to sleep or staying asleep with nonrestorative sleep is higher than the prevailing reported average; however, we are unaware of a study of well-characterized insomnia complaints in a population of North Americans as large as is this one.
The ARIC cohort was middle-aged (45-69 years); our findings indicated that "older" middle-aged individuals were less likely to endorse insomnia complaints than were those in their 40s. The prevalence of insomnia complaints is generally reported to increase with age, 2, 4, 5, [29] [30] [31] 33 but, after controlling for medical illness and other confounders, it appears that the healthy elderly sleep about as well as do younger people. 4, 28, 32, 33 Since we were able to control for medical illnesses, this finding is not unexpected.
As has been consistently reported in the literature, we found that women were more likely than men to endorse all sleep complaints, including insomnia complaints. However, there was no difference in the likelihood of sleep complaints for postmenopausal as compared with premenopausal women. We also replicated previous reports that insomnia complaints are more likely to be reported in individuals with lower incomes 29, 30, 34 and lower education attainment, 29, 30 controlling for age. Ohayon 2 has suggested that age could explain the association between income, education, and insomnia, but our data suggest that the relationships are independent of age. We confirmed that medical illness, especially hypertension, pulmonary disease and symptoms, and heart disease, are associated with an increased risk of insomnia complaints, as has been repeatedly reported. 2, 29 Although patients with insomnia have been reported to consume increased healthcare resources compared with those patients without insomnia, 3, 32, 33 it is not possible to determine if this increased cost is due to medical illness or to insomnia.
The relationship between insomnia complaints and depressive symptoms (and other mental disorders) is complex. Insomnia is reported by a majority of those with depression, and insomnia symptoms may precede the diagnosis of depression.
2,3 Because both depressive symptoms and insomnia complaints are identified primarily by symptom report, it is not possible to state whether or not insomnia complaints are simply an early marker of depression, rather than the cause. We screened for depressive symptoms using the Maastricht Questionnaire, 16 which was included as part of the data collected in the second ARIC visit. The Maastricht Questionnaire was originally developed to test the hypothesis that feelings of vital exhaustion precede the onset of myocardial infarction. Because the ARIC study was designed to investigate the risk of atherosclerotic disease, this questionnaire was most appropriate for that objective. While the Maastricht Questionnaire was not specifically designed to identify depression, a subset of its questions correlates strongly with other instruments used to assess depression 17 and has been used to assess depressive symptoms in other reports of the ARIC study population. 18 The 30.1% rate of depressive symptoms we found with this approach is higher than that generally reported for depression in the literature, but a recent report of the surgeon general notes that "depressive symptoms are far more common than full-fledged major depression…Eight to 20 percent of older adults in the community and up to 37% in primary care setting suffer from depressive symptoms." 35 This surgeon general's report focused on older adults, and a significant proportion of older adults are included in the ARIC cohort. Thus, the high prevalence of depressive symptoms, as opposed to major depressive disorder, found in this study is consistent with recent published reports. Based on data gathered by telephone survey of more than 1 million American Cancer Society volunteers, Kripke reported that reporting insomnia was associated with reduced mortality at 7-year follow-up. In that study, participants were asked, "On average, how many times a month do you have insomnia," and hazard ratios were calculated with "never" having insomnia being assigned a hazard ratio of 1. Compared with "never," any reported frequency of insomnia was associated with a statistically reduced risk of death 7 years later. Using a more precise definition of insomnia complaints, we confirm that insomnia complaints do not appear to confer an increased risk of death after controlling for confounders.
Kripke also reported that "prescription sleeping pill use" was associated with an increased risk of death, 11,14 a finding we are unable to confirm. However, the hazard ratio of 1.4 observed in our study somewhat exceeds that reported by Kripke et al. It is possible that the small numbers of participants in this study who were identified as taking hypnotics precluded our ability to identify a true risk of hypnotic use. A further weakness of our study is that the data did not include information about the frequency and duration of use and about the types of hypnotics (prescribed, over-the-counter, herbal or dietary supplements) that were used. This clearly limits our ability to draw strong conclusions about the effects of hypnotic use on this population.
In this large study of middle-aged adults, the prevalence of insomnia complaints with daytime complaints was 23%. Neither insomnia complaints nor hypnotic use predicted increased risk of death.
